2020
Risk factors for hepatocellular carcinoma (HCC) in the northeast of the United States: results of a case–control study
Shen Y, Risch H, Lu L, Ma X, Irwin ML, Lim JK, Taddei T, Pawlish K, Stroup A, Brown R, Wang Z, Jia W, Wong L, Mayne ST, Yu H. Risk factors for hepatocellular carcinoma (HCC) in the northeast of the United States: results of a case–control study. Cancer Causes & Control 2020, 31: 321-332. PMID: 32060838, PMCID: PMC7136513, DOI: 10.1007/s10552-020-01277-1.Peer-Reviewed Original ResearchConceptsRisk of HCCCase-control studyHepatocellular carcinomaRisk factorsHCV infectionHCC riskOdds ratioHepatitis C virus antibodyUnconditional logistic regression modelsElevated HCC riskRapid case ascertainmentC virus antibodyHeavy alcohol intakeConfidence intervalsFamily cancer historyImportant risk factorRandom digit dialingLow socioeconomic statusUnhealthy lifestyle choicesLower household incomeLogistic regression modelsNSAID useAlcohol intakeCigarette smokingHigher BMI
2010
ABO Blood Group, Helicobacter pylori Seropositivity, and Risk of Pancreatic Cancer: A Case–Control Study
Risch HA, Yu H, Lu L, Kidd MS. ABO Blood Group, Helicobacter pylori Seropositivity, and Risk of Pancreatic Cancer: A Case–Control Study. Journal Of The National Cancer Institute 2010, 102: 502-505. PMID: 20181960, PMCID: PMC2902822, DOI: 10.1093/jnci/djq007.Peer-Reviewed Original ResearchMeSH KeywordsABO Blood-Group SystemAdultAgedAged, 80 and overAntibodies, BacterialAntigens, BacterialBacterial ProteinsCase-Control StudiesConfounding Factors, EpidemiologicConnecticutEnzyme-Linked Immunosorbent AssayFemaleHelicobacter InfectionsHelicobacter pyloriHumansIncidenceMaleMiddle AgedOdds RatioPancreatic NeoplasmsConceptsNon-O blood typeH pylori seropositivityCase-control studyPancreatic cancerPylori seropositivityABO blood groupEnzyme-linked immunosorbent assayBlood typeBlood groupPopulation-based case-control studyNon-O blood groupControl subjects frequencyH pylori colonizationVirulence protein CagAHelicobacter pylori seropositivityPancreatic cancer riskO blood typeRandom digit dialingCagA seropositivityCase patientsH pyloriControl subjectsRisk factorsPylori colonizationCancer risk
2000
Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer
Farrow D, Vaughan T, Sweeney C, Gammon M, Chow W, Risch H, Stanford J, Hansten P, Mayne S, Schoenberg J, Rotterdam H, Ahsan H, West A, Dubrow R, Fraumeni J, Blot W. Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes & Control 2000, 11: 231-238. PMID: 10782657, DOI: 10.1023/a:1008913828105.Peer-Reviewed Original ResearchConceptsGastroesophageal reflux diseaseNon-cardia gastric adenocarcinomaEsophageal adenocarcinomaGERD symptomsReflux diseaseH2 blockersGastric adenocarcinomaGastric cancerLarge population-based case-control studyPopulation-based case-control studyPopulation-based tumor registryEsophageal squamous cell carcinomaPerson structured interviewRisk of esophagealSquamous cell carcinomaEsophageal adenocarcinoma riskH2-receptor antagonistsCase-control studyGastric cardia adenocarcinomaRandom digit dialingLong-term usersTumor RegistryAdenocarcinoma riskDaily symptomsCell carcinoma